Our Services
Medical Information
Helpful Resources
Published on: 6/14/2026
Long-term GLP-1 therapy may cause persistent gastrointestinal discomfort, gallstones, and changes in pancreatic, gallbladder, and thyroid health. Doctors also monitor for nutrient deficiencies, kidney and cardiovascular effects, injection-site reactions, and mental health shifts.
Key monitoring strategies, recommended labs, and patient tips are outlined below to help guide safe, long-term use.
Because GLP-1 side effects can mimic other conditions and vary widely from person to person, the smartest first step is to clarify what your symptoms actually mean. Take a free, instant, online symptom check to better understand what's going on, identify red flags early, and navigate your next steps with confidence.
Reviewed for medical accuracy: 06/14/2026
GLP-1 receptor agonists (such as semaglutide, liraglutide and dulaglutide) have revolutionized the treatment of type 2 diabetes and obesity. As more patients stay on these medications for years, "GLP-1 side effects long term" is a key concern—for both clinicians and users. Below, we summarize what your doctor is watching for beyond the first 12 months of therapy, and what you can do to stay on track with safety and health.
Most people know GLP-1 drugs can cause nausea or constipation early on. But long-term use can lead to:
Tip for Patients:
Keep a simple symptom diary. Note stool frequency and any persistent discomfort, and share it at visits.
Concerns about pancreatitis arose early in GLP-1 use, though large studies haven't confirmed a strong link long term.
Patient Action:
Seek prompt evaluation for any severe, unrelenting belly pain or unexplained nausea/vomiting.
Weight loss itself can raise gallstone risk. GLP-1 therapies may accelerate that effect.
Note:
Report any sharp, cramping pain under your ribs—especially if it radiates to your back or shoulder.
Animal studies raised concerns about C-cell tumors, but human data remain reassuring.
Significant weight loss can unmask or cause:
Tip for Patients:
Aim for small, frequent meals with a mix of protein, healthy fats and fiber to support steady weight loss and nutrient intake.
Rapid weight loss and changes in blood sugar can affect kidney function, especially if you're on other medications (e.g., SGLT2 inhibitors).
GLP-1 drugs often lower blood pressure and improve heart health, but vigilance remains key.
Patient Note:
Keep track of home blood pressure readings, especially if you feel dizzy upon standing.
Most GLP-1 drugs are injectable. Over time, your body may develop antibodies, though clinical impact is rare.
Changes in appetite, body image and mood can arise over prolonged use.
Although uncommon, certain issues warrant immediate attention:
If you experience any of these, please seek emergency care.
If you're experiencing any new or unusual symptoms between appointments, use Ubie's Medically approved LLM Symptom Checker Chat Bot to help you understand your symptoms and determine whether they require immediate attention or can wait until your next scheduled visit.
Even with careful monitoring, some changes need a provider's input:
Always reach out if you feel something isn't right. If you experience any life-threatening or serious symptoms, seek medical attention immediately.
By partnering with your healthcare team and staying informed, you can continue to reap the benefits of GLP-1 therapy while minimizing potential risks over the years.
(References)
* Abd elaziz H, Gamil I, Tawfik M, et al. Safety and Tolerability of Long-Term Treatment with GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. Diabetes Ther. 2020 Jul;11(7):1387-1406. doi: 10.1007/s13300-020-00818-5. Epub 2020 May 16. PMID: 32414002; PMCID: PMC7304561.
* Lingvay I, Mosenzon O, Mosenzon O, et al. Long-term safety and efficacy of once-weekly semaglutide in patients with type 2 diabetes: a 3-year post-hoc analysis of SUSTAIN trials. Diabetes Obes Metab. 2021 Jul;23(7):1943-1953. doi: 10.1111/dom.14418. Epub 2021 Apr 6. PMID: 33827533; PMCID: PMC8252277.
* Al-Qurashi MM, Abumansour H, Abusurrah A, et al. Cardiovascular and Renal Outcomes with Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2023 Aug 18;15(8):e43702. doi: 10.7759/cureus.43702. PMID: 37626992; PMCID: PMC10438186.
* Yang D, He J, Peng F, et al. Safety and efficacy of GLP-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of long-term randomized controlled trials. J Cell Mol Med. 2020 May;24(9):4927-4940. doi: 10.1111/jcmm.15175. Epub 2020 Mar 17. PMID: 32185244; PMCID: PMC7219904.
* Sun T, Liu Y, Li H, et al. Risk of cholelithiasis and cholecystitis with glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2022 Oct;15(10):1249-1259. doi: 10.1080/17512433.2022.2110651. Epub 2022 Aug 4. PMID: 35922378.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.